Johnson & Johnson and Protagonist secured FDA approval for Icotyde (icotrokinra), an oral IL‑23 receptor antagonist for moderate‑to‑severe plaque psoriasis in adults and adolescents. The approval follows a large Iconic program of four phase III trials with about 2,500 patients and head‑to‑head studies against active comparators. J&J projects peak sales in the multibillion‑dollar range and positions Icotyde as a convenient, once‑daily alternative to injectable IL‑23 biologics. The label covers key disease sites and pediatric patients down to age 12 (≥40 kg). Payers and dermatology clinics will evaluate switching patterns and cost‑effectiveness compared with established biologics. Market analysts expect Icotyde to expand the treated population by lowering the barrier to systemic therapy; companies with injectable franchises are reassessing lifecycle strategies and potential oral competitors.